JD Capital-Invested Novocare Gets Listed on NEEQ


Lately, JD Capital-invested Shenzhen Novocare Medical Equipment Co., Ltd (“Novocare”) successfully became a listed company on the National Equities Exchange and Quotations (NEEQ).

Novocare: expert curator for life and health

Novocare is mainly engaged in the R&D, manufacturing and sales of “non-disturbing” medical equipment for life information monitoring. Focusing on breakthroughs and innovations in “non-disturbing” vital sign monitoring techniques, the company has built technical platforms for system development, health management and algorithm integration, and is devoted to medical equipment for vital signs collection and monitoring with high sensitivity, confident and stability.

Its products provide continuous vital signs monitoring service mainly for those with serious cardio cerebrovascular diseases or with high risks of sudden death, in an effort to reduce mortality. So far, the company has finished development of its first-generation product and has obtained its registration certificate and production license. Meanwhile, there are four other products at the stage of registration or R&D.

Data from Arrhythmia Alliance show that, every year, 540,000 people in China suffer from sudden cardiac deaths, among which over 90% are patients of cardio cerebrovascular diseases. Novocare’s monitoring products are able to realize continuous user-targeted monitoring of dynamic vital signs at night. Real-time monitoring data can be transmitted and displayed at the back-stage data screen prepared by the hospital or company. On that basis, a reaction and control system will be built up in a timely and effective manner, which greatly saves rescue time and increases ratio of successful rescue.

Besides, its products are also capable of providing convenient real-time statistics of sickbed management and patient information for family nursing, hospitals, nursing homes and other institutions, and reducing caring and management costs for matters such as nightly visits.

In 2015, a fund managed by JD Capital became one of Novocare’s shareholders, holding 10.44% of its shares prior to its listing.